Open Internet by MindsNet

Targeting the KRAS G12D mutation in pancreatic cancer

The KRAS G12D mutation in pancreatic cancer is considered 'undruggable', presenting a significant challenge in finding effective treatments. This mutation is a major bottleneck in pancreatic cancer therapy, leading to a substantial unmet need for targeted therapies. Current treatments often fail to effectively target this specific mutation, resulting in limited patient outcomes.

Science, Biology, Cell Biology